Working Groups

Active?
Facet Toggle

A New Grand Bargain to Improve the Antimicrobial Market for Human Health
Amanda Glassman
et al.
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
Incorporating Economics and Modelling in Global Health Goals and Guidelines
Amanda Glassman
et al.
November 15, 2017
International organizations influence national-level health sector priorities by affecting how much funding is available for healthcare delivery within countries and setting limits on how that funding is used. They exert particular influence in setting disease-specific targets, developing clinical g...
Working Group on the Future of Global Health Procurement
Amanda Glassman
et al.
July 31, 2017
Many low-and lower-middle-income countries currently procure a large portion of their health commodities through centralized, donor-managed procurement mechanisms, and often at subsidized prices or as donations. Over the next several decades, however, the landscape of global health procurement will ...
Next Generation Financing Models in Global Health
Amanda Glassman
et al.
August 19, 2015
The Unintended Consequences of Rich Countries’ Anti–Money Laundering Policies on Poor Countries
Alan Gelb
et al.
January 23, 2015
The Unintended Consequences of Rich Countries’ Anti-Money Laundering Policies on Poor Countries Working Group examined how rich countries might rebalance their policies to continue to protect against money laundering and terrorism financing without hindering the ability of people from poor countries...
Drug Resistance Working Group (November 2007 – June 2010)
Amanda Glassman
and
Prashant Yadav
September 10, 2014
Priority-Setting Institutions for Global Health
Amanda Glassman
and
Kalipso Chalkidou
September 10, 2014
If you have $200 to spend on health in a developing country, would you vaccinate 10 children against deadly childhood diseases or provide AIDS treatment to one woman to prevent transmission of HIV to her unborn child? Policy makers routinely face such tough budgetary dilemmas with little expert guid...
Value for Money: An Agenda for Global Health Funding Agencies
Amanda Glassman
et al.
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM)  agenda aims to reduce costs, increase imp...